Cryosite Ltd
Company Profile
Business description
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
Contact
13a Ferndell Street
South Granville
SydneyNSW2142
AUST: +61 288652000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
25
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.50 | 23.70 | -0.27% |
| CAC 40 | 8,086.05 | 20.11 | -0.25% |
| DAX 40 | 23,960.59 | 116.28 | -0.48% |
| Dow JONES (US) | 47,885.97 | 228.29 | -0.47% |
| FTSE 100 | 9,774.32 | 89.53 | 0.92% |
| HKSE | 25,366.47 | 102.31 | -0.40% |
| NASDAQ | 22,693.32 | 418.14 | -1.81% |
| Nikkei 225 | 48,916.94 | 595.34 | -1.20% |
| NZX 50 Index | 13,251.57 | 44.34 | -0.33% |
| S&P 500 | 6,721.43 | 78.83 | -1.16% |
| S&P/ASX 200 | 8,564.60 | 20.60 | -0.24% |
| SSE Composite Index | 3,876.40 | 6.12 | 0.16% |